Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,435 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.3
Industry P/E
--
EV/EBITDA
-2.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.6
Face value
--
Shares outstanding
105,200,000
CFO
$-201.90 Mln
EBITDA
$-203.92 Mln
Net Profit
$-184.24 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Edgewise Therapeutics (EWTX)
| -49.3 | -6.6 | 0.7 | -37.0 | 10.0 | -- | -- |
|
BSE Sensex
| 4.5 | 0.2 | 4.1 | 1.3 | 15.0 | 17.2 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Edgewise Therapeutics (EWTX)
| 142.3 | 22.4 | -41.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Edgewise Therapeutics (EWTX)
|
13.5 | 1,434.9 | 0.0 | -146.1 | -- | -31.8 | -- | 3.3 |
| 52.0 | 8,119.0 | 1,208.8 | 131.7 | 16.8 | 6.3 | 62.4 | 4.1 | |
| 129.5 | 8,360.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 18.0 | |
| 50.5 | 10,124.2 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.3 | |
| 44.5 | 12,220.1 | 2,298.9 | 643.6 | 35.4 | 29.2 | 20.5 | 5.8 | |
| 334.1 | 7,659.5 | 317.4 | -391.6 | -118.9 | -52.6 | -- | 10.8 | |
| 311.9 | 9,048.7 | 2,156.6 | 416.4 | 21.2 | 56.5 | 24 | 15.2 | |
| 31.3 | 12,399.0 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.2 | |
| 132.0 | 13,210.0 | 2,412.6 | 305.8 | 20.5 | 11.6 | 45.2 | 5.3 | |
| 292.0 | 13,449.0 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.9 | 1.9 |
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II... clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado. Address: 1715 38th Street, Boulder, CO, United States, 80301 Read more
Co-Founder & Independent Chairman
Dr. Peter A. Thompson FACP, M.D.
Co-Founder & Independent Chairman
Dr. Peter A. Thompson FACP, M.D.
Headquarters
Boulder, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Edgewise Therapeutics Inc (EWTX) stood at $ 476 Mln as on 31-Mar-25
The share price of Edgewise Therapeutics Inc (EWTX) is $13.54 (NASDAQ) as of 18-Jul-2025 16:00 EDT. Edgewise Therapeutics Inc (EWTX) has given a return of 10.05% in the last 3 years.
Edgewise Therapeutics Inc (EWTX) has a market capitalisation of $ 1,435 Mln as on 17-Jul-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Edgewise Therapeutics Inc (EWTX) is 3.34 times as on 17-Jul-2025, a 5% premium to its peers’ median range of 3.18 times.
Since, TTM earnings of Edgewise Therapeutics Inc (EWTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Edgewise Therapeutics Inc (EWTX) and enter the required number of quantities and click on buy to purchase the shares of Edgewise Therapeutics Inc (EWTX).
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado. Address: 1715 38th Street, Boulder, CO, United States, 80301
The CEO & director of Dr. Peter A. Thompson FACP, M.D.. is Edgewise Therapeutics Inc (EWTX), and CFO & Sr. VP is Dr. Peter A. Thompson FACP, M.D..
There is no promoter pledging in Edgewise Therapeutics Inc (EWTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,345
|
|
|
1,321
|
|
|
1,240
|
|
|
1,222
|
|
|
1,012
|
|
|
905
|
|
|
836
|
|
|
812
|
|
|
766
|
| Edgewise Therapeutics Inc. (EWTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-31.81
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Edgewise Therapeutics Inc (EWTX) was $0 Mln.
$-0.19
(
